Metabolic changes in psoriatic skin under topical corticosteroid treatment

BMC Family Practice

Tone Frost Bathen³  Jostein Halgunset¹  Margareta Karin Johnsson⁴  Beathe Sitter² 

[1]Department of Pathology and Medical Genetics, St. Olavs Hospital HF, Trondheim University Hospital, Trondheim, Norway

[2]Department of Technology, Sør Trøndelag University College, 7004 Trondheim, Norway

[3]Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway

[4]Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

关键词: MR spectroscopy;    Psoriasis treatment;    Corticosteroids;    Metabolites;    Tissue;   

Others  :  855053
DOI  :  10.1186/1471-5945-13-8

 received in 2013-02-10, accepted in 2013-08-08,  发布年份 2013

【 摘 要 】

Background

MR spectroscopy of intact biopsies can provide a metabolic snapshot of the investigated tissue. The aim of the present study was to explore the metabolic pattern of uninvolved skin, psoriatic skin and corticosteroid treated psoriatic skin.

Methods

The three types of skin biopsy samples were excised from patients with psoriasis (N = 10). Lesions were evaluated clinically, and tissue biopsies were excised and analyzed by one-dimensional ¹H MR spectroscopy. Relative levels were calculated for nine tissue metabolites. Subsequently, relative amounts of epidermis, dermis and subcutaneous tissue were scored by histopathological evaluation of HES stained sections.

Results

Seven out of 10 patients experienced at least 40% reduction in clinical score after corticosteroid treatment. Tissue biopsies from psoriatic skin contained lower levels of the metabolites myo-inositol and glucose, and higher levels of choline and taurine compared to uninvolved skin. In corticosteroid treated psoriatic skin, tissue levels of glucose, myo-inositol, GPC and glycine were increased, whereas choline was reduced, in patients with good therapeutic effect. These tissue levels are becoming more similar to metabolite levels in uninvolved skin.

Conclusion

This MR method demonstrates that metabolism in psoriatic skin becomes similar to that of uninvolved skin after effective corticosteroid treatment. MR profiling of skin lesions reflect metabolic alterations related to pathogenesis and treatment effects.

【 授权许可】

   
2013 Sitter et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Nestle FO, Kaplan DH, Barker J: Psoriasis. N Engl J Med 2009, 361:496-509.
• [2]Gottlieb AB, Dann F: Comorbidities in patients with psoriasis. Am J Med 2009, 122:1150-1159.
• [3]Hughes J, Rustin M: Corticosteroids. Clin Dermatol 1997, 15:715-721.
• [4]Reich K, Bewley A: What is new in topical therapy for psoriasis? J Eur Acad Dermatol Venereol 2011, 25(Suppl 4):15-20.
• [5]Millikan LE: Drug therapy in dermatology. New York: Dekker; 2000.
• [6]Bowes J, Barton A: The genetics of psoriatic arthritis: lessons from genome-wide association studies. Discov Med 2010, 10:177-183.
• [7]Caruso R, Botti E, Sarra M, Esposito M, Stolfi C, Diluvio L, Giustizieri ML, Pacciani V, Mazzotta A, Campione E, Macdonald TT, Chimenti S, Pallone F, Costanzo A, Monteleone G: Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 2009, 15:1013-1015.
• [8]Liu Y, Krueger JG, Bowcock AM: Psoriasis: genetic associations and immune system changes. Genes Immun 2007, 8:1-12.
• [9]Lindon JC, Beckonert OP, Holmes E, Nicholson JK: High-resolution magic angle spinning NMR spectroscopy: application to biomedical studies. Prog Nucl Magn Reson Spectrosc 2009, 55:79-100.
• [10]Bathen TF, Sitter B, Sjobakk TE, Tessem MB, Gribbestad IS: Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation. Cancer Res 2010, 70:6692-6696.
• [11]Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS: Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed 2006, 19:30-40.
• [12]Sitter B, Sonnewald U, Spraul M, Fjosne HE, Gribbestad IS: High-resolution magic angle spinning MRS of breast cancer tissue. NMR in Biomedicine 2002, 15:327-337.
• [13]Martinez-Bisbal MC, Marti-Bonmati L, Piquer J, Revert A, Ferrer P, Llacer JL, Piotto M, Assemat O, Celda B: 1H and 13C HR-MAS spectroscopy of intact biopsy samples ex vivo and in vivo 1H MRS study of human high grade gliomas. NMR Biomed 2004, 17:191-205.
• [14]Kim YH, Orenberg EK, Faull KF, Wade-Jardetzky NG, Jardetzky O: 1H NMR spectroscopy: an approach to evaluation of diseased skin in vivo. J Invest Dermatol 1989, 92(2):210-216.
• [15]Weibel ER, Kistler GS, Scherle WF: Practical stereological methods for morphometric cytology. J Cell Biol 1966, 30:23-38.
• [16]van Waarde A, Elsinga PH: Proliferation markers for the differential diagnosis of tumor and inflammation. Curr Pharm Des 2008, 14:3326-3339.
• [17]Borgan E, Sitter B, Lingjaerde OC, Johnsen H, Lundgren S, Bathen TF, Sorlie T, Borresen-Dale AL, Gribbestad IS: Merging transcriptomics and metabolomics–advances in breast cancer profiling. BMC Cancer 2010, 10:628. BioMed Central Full Text
• [18]Sitter B, Bathen TF, Singstad TE, Fjosne HE, Lundgren S, Halgunset J, Gribbestad IS: Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed 2010, 23:424-431.
• [19]Cuperlovic-Culf M, Chute IC, Culf AS, Touaibia M, Ghosh A, Griffiths S, Tulpan D, Leger S, Belkaid A, Surette ME, Ouellette RJ: (1)H NMR metabolomics combined with gene expression analysis for the determination of major metabolic differences between subtypes of breast cell lines. Chem Sci 2011, 2:2263-2270.